RELiZORB Is Specifically Designed to Deliver More Absorbable Calories from Enteral Formula
In controlled studies using a well-established porcine model of exocrine pancreatic insufficiency, RELiZORB increased plasma levels of omega-3 fats (docosahexaenoic acid [DHA] and eicosapentaenoic acid [EPA]).
Formula hydrolyzed with RELiZORB was associated with a statistically significant increase in total fat absorption and improvement in uptake of omega-3 fatty acids (DHA and EPA) in plasma level over 24 hours compared with non-hydrolyzed formula without RELiZORB (P<0.05).†
RELiZORB use increased plasma levels of omega-3 (DHA and EPA) in preclinical studies.
RELiZORB normalized plasma levels of DHA and EPA in a controlled study using a well-established porcine model of exocrine pancreatic insufficiency, as seen in the figure below.
RELiZORB use enhanced fat absorption and caloric intake in preclinical studies, as demonstrated by improved plasma levels of DHA and EPA over 12 days.‡
DHA (docosahexaenoic acid) and EPA (eicosapentaenoic acid) measured as ng/ml. Results are shown as a mean group ± SD.
Studies performed in a porcine model of exocrine pancreatic insufficiency. The clinical significance of these observations has not been determined.
P= 0.008 difference between RELiZORB vs. No RELiZORB for DHA.
Higher levels of fat-soluble vitamins (D and E) were observed with use of RELiZORB after 12 days.¶
The following formulas have been evaluated for use with RELiZORB and have demonstrated the hydrolysis levels shown below. Testing conditions were 500 mL of formula with a pump rate of 120 mL/hr.
** % fat hydrolysis is estimated based on label claim fat content.
†† Fat hydrolysis rates are similar over the shelf life of RELiZORB.
Note: Formula manufacturers may change the composition of their formulas, which may affect the operation of RELiZORB. Please refer to formula product websites for recent product descriptions, ingredients, and nutritional information. If you have questions about whether your formula can be used with RELiZORB, please contact RELiZORB Support Services at 1-844-632-9271.